4 Stocks You'll Be Glad You Bought at These Prices

No one can tell you for certain whether this coronavirus bear market is over for good, or if another major sell-off is on the horizon. What is certain, though, is that while COVID-19 cases continue to grow in both the U.S. and around the world, it's completely altered the way many companies are now doing business.

While for some, this change is for the worse, other businesses are set to surge during this time. Even better, most of these companies that are poised to do well are still trading at steep discounts compared to where they were just a month ago.

Here are four stocks you'll be glad you bought now rather than later.

Image source: Getty Images.

1.

With most people choosing to stay at home rather than venture about due to COVID-19, it's not surprising that many have turned to online shopping as an alternative to going in person. As such, e-commerce companies are expected to have one of their best years on record due to this pandemic.

As the largest online retailer, Amazon (NASDAQ:AMZN)is expected to do extremely well this year. The company announced it would hire anextra 100,000 workersto keep up with its increased online orders, and as outbreaks in the U.S. continue to worsen, demand should continue to skyrocket.

Despite its size, Amazon had been reporting tremendous growth even before the coronavirus outbreak began. Annual revenue had more than doubled between 2015 and 2019, growing from $107 billion to $280.5 billion. This is the kind of growth expected from a young tech company, which makes it all the more impressive that it's a company with almost a trillion-dollar market valuation. With Amazon's stock still trading at a discount in comparison to its previous February highs, now's a good time for investors to pick up shares at an attractive price while they can.

2. AMD

(NASDAQ:AMD)has done very well over the past couple of years, seizing the PC processor market by storm and edging out over its major competitors. Last year's release of its Ryzen 3000 desktop processors are still going strong, while excitement surrounding its upcoming Ryzen 4000 series (scheduled to be released this year) is growing as well.

Putting aside its processors, AMD is expected to see a significant boost in data center demand as companies all around the world encourage their employees to work from home. Although

currently remains the dominant player in the data center market, this is expected to change significantly over the next year or two as AMD's market share grows.

Financially, AMD's growth has been phenomenal. Revenue between Q4 2018 and Q4 2019 grew by around 50% to $2.1 billion. Profit margins have improved by a further 7% during that period, up to 45%, while AMD's bottom line has more than quadrupled, hitting $170 million in Q4 2019.

Despite bullish expectations for the company, AMD is still trading at around a 20% discount from its all-time high in mid-February. With the company's long-term prognosis looking better than ever, AMD looks like a good deal for growth-oriented investors looking for an excellent investment at a cheap price.

Image source: Getty Images.

3.

There are a number of large-cappharmaceuticalcompanies trading at extraordinarily cheap valuations.

AbbVie

(NYSE:ABBV)is one of them. While there's still a bit of lingering concern regarding the patent expiration of the company's top-selling drug, Humira, AbbVie has prepared an impressive line-up of potential blockbuster drugs to make up for Humira's projected revenue decline.

Besides its promising new immunology drugs, Skyrizi and Rinvoq, the AbbVie's acquisition of

will expand the healthcare giant's pipeline for the better. In addition to Humira, AbbVie's second top-selling drug, Imbruvica, brought in $3.8 billion in revenue during Q4 2019. That's a 30.2% increase from last year.

Despite its strong drug lineup, AbbVie trades at an extraordinarily cheap valuation. The company has a price-to-sales ratio of 3.2 and a price-to-equity ratio of 13.8. To sweeten the deal, AbbVie has a 6.5% dividend yield at its current price, which makes it an incredibly appealing company for investors who appreciate a high dividend.

4. CVS Health

Most companies directly involved in fighting the COVID-19 pandemic have seen their shares surge over the past month. However, that hasn't been the case across the board. Pharmacy retailer

CVS Health

(NYSE:CVS)saw its shares plunge to a 52-week low earlier in March.

However, as COVID-19 continues to spread in the U.S., long-term demand for its pharmaceutical and sanitary products are expected to shoot up. CVS Health has already announced that it would hire anadditional 50,000full-time, part-time, and temporary staff members to meet demand from customers across the country.

Currently, CVS Health trades at a measly 0.3 P/S ratio and a 11.4 P/E ratio. At the same time, the company offers a healthy 3.4% dividend yield. While shares of CVS are still trading quite low, strong demand for its products and the burgeoning number of COVID-19 patients in the U.S. are expected to help move the stock back to a normal price range soon.

没有人能确切地告诉你，这场冠状病毒熊市是�崾硪怀〈Ｅ资奂唇嚼础２还梢钥隙ǖ氖牵」蹸OVID-19�诿拦褪澜绺荚谠耆谋淞诵矶喙鞠衷诘木绞健�

虽然对一些人来说，这一变化更糟，但在这段时间内，其他�步８玫氖牵胍桓跋啾龋急缸淮淼墓救栽谝源劭鄣募鄹薪灰住�

这里有四只你现在�善保皇且院摹�

图片来源：Getty图片。1.Amazon.com

由于COVID-19的原�搜≡诩依锒皇敲跋眨矶嗳搜≡瞎何铮皇乔鬃匀ス何铮庖坏阋簿筒蛔阄媪恕Ｒ捎谡庖涣。缱由涛居型从屑锹家岳醋詈玫囊荒辍�

�畲谙吡闶凵蹋锹硌�(NASDAQ：AMZN)�谋硐纸浅３８霉拘迹钔夤陀�10�惫ぃ愿显谙叨┑サ脑Ｋ孀琶拦咔槌中枨绦�

尽管亚马逊的规模很�诠谧床《颈⒅埃锹硌肪捅ǜ媪怂木薮ぁ�2015年至2019年期间，公司年收入翻了一番多，从1070亿美元�805亿美元。这是一家年轻的科技公司的预期�馐沟盟恿钊擞∠蹋且患矣涤薪涝谐」乐档墓尽Ｓ捎谘锹硌返墓杉廴缘陀�2月份的高点，�衷谑峭蹲收咴诳赡艿那榭杂形Φ募鄹牍善钡暮檬被�2.AMD

先进微设备公司(NASDAQ：AMD)在过去的几年里取得了很好的成绩，抢占了PC处理�。⒂肫渲赫允志赫Ｈツ攴⒉嫉腞yzen 3000桌面处理�谇烤⒎⒄梗嗣嵌云浼唇瞥yzen 4000系列(定于�⒉�)的兴奋情�谠�

撇开处理�福孀攀澜绺墓竟睦惫ぴ诩夜ぷMD的数据中心需�平Ｋ淙挥⑻囟壳叭允鞘葜行氖谐〉闹蹋孀臕MD市场份额的�庖磺ぜ平谖蠢匆涣侥攴⑸卮�

在财�珹MD的�蔷说摹�2018年第4季度至2019年第4季度的收入�嗽�50%，达到21亿美元。同期利�痔岣吡�7%，达到45%，而AMD的利�ち肆奖抖啵�2019年第四季度达到1.7亿美元。

尽管AMD对该公司抱有乐观的预期，但其股价仍较2月中旬的历史高点折让约20%。随着公司的长期预测看�纫酝魏问焙茫珹MD看�且桓玫慕灰祝嫦ば偷耐蹲收撸罢乙桓愕耐蹲剩缘土募鄹/p>

图片来源：Getty图片。3.AbbVie

有许多�埔┕镜墓乐导汀bbVie(纽约证券交易所代码：ABBV)就是其中之一。尽管对于该公司最畅销的药物Humira的专利到期仍有一些挥之不去的担忧，abbvie已经准备了一系列令人印�痰那痹诖┪铮悦植笻umira预计的收入下降。

除了有希望的新免疫药物Skyrizi和Rvoq，AbbVie收购Allergan将使这家医疗巨头的管道变得更好。除了Humira，AbbVie的第二�┪颕mbruvica在2019年第四季度带来了38亿美元的收入。这比去年��30.2%。

尽管拥有强�酒氛珹bbVie的股价却非常便宜。该公司的售价与销售额之比为3.2，股价与股本之比为13.8.为了使这笔交易雪上加霜，AbbVie目前的股息收益率为6.5%，这使得它成为一家非常有吸引力的公司，�蹲收呦不陡吖上ⅰ�4.CVS健康

�苯硬斡攵钥笴OVID-19�械墓荆涔杉墼诠ヒ桓锒汲遂Ｈ欢榭侨绱恕Ｒ揭┝闶凵藽VSHealth(纽约证券交易所市场代码：CVS)在3月�鄣�52周低点。

然而，随着COVID-19继续在美国蔓延，对其药品和卫生产品的长期需�平ぴVS健康公司已经宣布，将再雇佣5�啊⒓嬷昂土偈痹惫ぃ月闳突У男枨/p>

目前，CVS的市盈率�.3P/S，市盈率为11.4。与此同时，该公司提供了一�档�3.4%的股息收益率。尽管CVS的股价仍然很低，但市场对其产品的强劲需�霸诿拦腃OVID-19患者数量的激�ぜ平兄诟霉镜墓杉酆芸旎氐秸＜鄹洹�

免�形姆胗商谘斗刖峁┲С郑煌径苑胄畔⒌淖既沸曰啃运斐傻娜魏嗡怀械Ｈ魏卧�